---
title: "Bank of America Names 2 'Strong Buy' Stocks With 60%+ Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305294459.md"
description: "Bank of America identified two biotech stocks with 'Strong Buy' ratings and over 60% upside potential, highlighting Iambic Therapeutics (IAM). IAM utilizes AI-driven drug discovery, partnering with major pharma firms like Takeda. Its lead candidate, IAM1363, shows promising clinical results for HER2-positive cancers, including brain metastases. Following a recent IPO raising $150 million, BofA analysts cite the platform's speed and clinical data as key drivers for its bullish outlook."
datetime: "2026-11-12T10:27:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305294459.md)
  - [en](https://longbridge.com/en/news/305294459.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305294459.md)
generator: "portal-rs"
---

# Bank of America Names 2 'Strong Buy' Stocks With 60%+ Upside

Biotech stocks have been among the market's stronger performers this year, benefiting from advances in drug development, growing interest in AI, and increased merger and acquisition activity. Investors have become more willing to put money into the sector as companies make progress on new treatments and look for ways to bring promising therapies to market.

The sector's performance reflects that growing confidence; the State Street SPDR S&P Biotech ETF (XBI) has climbed 28% year-to-date, easily outperforming the S&P 500's 11% gain over the same period.

Bank of America believes the rally may have further to run, particularly for companies with promising drug pipelines and upcoming catalysts. The firm's analysts have singled out two biotech stocks with upside potential of at least 60% from current levels.

Running the tickers through TipRanks' database, we learned the both have also earned a "Strong Buy" consensus rating from the rest of the Street. Let's take a closer look.

**Iambic Therapeutics** **(IAM)**

The first BofA pick, Iambic Therapeutics, brings cutting-edge technology to bear on clinical-stage biotech research, in a move that the company describes as a "fundamental shift in the biopharmaceutical industry." Put simply, Iambic is using large-scale AI to improve the industry's automated and scalable experiments in chemistry and biology. Iambic is using a proprietary AI platform and has dubbed its approach "molecular superintelligence."

Iambic's platform is designed to follow several paths simultaneously to speed up and improve drug development. The Enchant v3 section of the platform is a multimodal transformer, acting as the platform's brain and predicting preclinical and clinical endpoints across the company's pipeline of drug candidates. The model uses 41 billion parameters, was pretrained on 4.5 trillion tokens, and supports optimization across more than 6,000 molecular properties. The platform's NeuralPLexer3 uses AI technology, including flow matching and physics-based principles, to predict three-dimensional protein structures and protein-ligand complexes.

Iambic's technology has also attracted interest from some of the pharmaceutical industry's biggest names. The company has established collaborations with AbbVie, Bayer, Takeda, and Lundbeck, among others, to apply its AI capabilities to drug discovery across several therapeutic areas. Its agreement with Takeda, announced in February, includes the potential for more than $1.7 billion in success-based payments, although those amounts depend on achieving future milestones. The partnerships give Iambic opportunities to generate revenue from its technology while continuing to develop its own medicines.

Using this platform, Iambic has put together a pipeline of drug candidates designed to target various cancers. The first of these to enter clinical trials, IAM1363, progressed from project initiation to clinical development in approximately two years – a much faster pace than the industry average. The drug is designed to treat cancers driven by wild-type and mutant HER2 proteins.

The company is also making progress with IAM217, its second wholly owned AI-discovered drug candidate. On October 5, Iambic announced that it had submitted an Investigational New Drug (IND) application to the FDA, seeking permission to begin a Phase 1/2 clinical trial. The drug targets KIF18A, a protein involved in cell division, and is being developed for triple-negative breast cancer, ovarian cancer, and other solid tumors. Preclinical research has also shown encouraging results against tumors in the brain, although its effectiveness in humans remains unproven.

Meanwhile, Iambic recently announced that IAM1363, currently in a Phase 1/1b clinical trial, has demonstrated a favorable tolerability profile. More than half of the patients receiving the 960 mg dose remain on treatment, with some continuing beyond one year. The company also reports durable anti-tumor activity, including responses in patients who had already received several previous cancer treatments.

Perhaps more encouraging are the drug's early results in patients with brain metastases. Iambic reported confirmed intracranial partial responses in three patients with HER2-positive breast cancer who had previously received Enhertu (T-DXd) and tucatinib. All three remained on treatment at the time of the clinical update, including one patient who had more than 50 brain metastases. These findings suggest that IAM1363 may offer another treatment option for patients with limited alternatives, although larger studies will be needed to establish its effectiveness.

Last month, Iambic went public in an IPO to raise capital for further operations, including its continuing clinical trials, AI platform development, and preclinical drug candidate research and regulatory submissions. The company put its stock on the market on October 15, making 9,375,000 shares available at $16 each and raising $150 million in gross proceeds.

BofA analyst Alec Stranahan is bullish on this biotech, and his stance is based on the quality, and trial success, of IAM1363.

"Iambic is one of the few AI drug discovery companies with clinical data supporting its platform. Its lead asset IAM1363 (HER2) went from program start to the clinic in about two years. The ESMO 2026 update moved the drug past early signs of activity. Across 53 patients with targetable HER2 alterations dosed at ≥960mg, the partial response rate was 36%. The intracranial response rate was 41% (9/22), in a population where 61% had prior T-DXd and 36% had prior tucatinib. Over half of patients on the 960mg recommended dose remain on study, and some have been treated for more than a year. We see '1363 as a credible brain-penetrant option for HER2-driven tumors, with a registrational trial possible as early as 2027. Shares have also sold off since IPO along with the broader AI basket, which we see as providing a particularly attractive entry point in companies like Iambic which are pushing forward tangible applications of AI," Stranahan wrote. 

The BofA expert puts a Buy rating on IAM, seeing plenty of upside in the platform and the clinical trials. He complements that rating with a $30 price target that implies a 95% gain in the next 12 months. (To watch Stranahan's track record, click here)

While there are only 3 recent analyst reviews on file for this new stock, they are all positive, giving IAM its unanimously positive Strong Buy consensus rating. The shares are priced at $15.39 and the $28.50 average price target indicates a one-year upside of 85%. (See IAM stock forecast)

**Supernus, Inc.** **(SUPN)**

Next on BofA's radar is Supernus, a pharmaceutical company that focuses on central nervous system (CNS) disorders and has a solid portfolio of approved medications on the market. Supernus has more than 30 years of expertise in the business, and its lineup of drugs includes treatments for Parkinson's disease, epilepsy, opioid use disorder (OUD), postpartum depression (PPD), ADHD, and migraine.

The big news right now for Supernus, however, is not from the pipeline or portfolio – it is from the business side. On November 2, Supernus completed a 'merger of equals' transaction with Indivior Pharmaceuticals and created a joint company that brings together both approved drug portfolios and backs that with a combined research pipeline. The combined entity retained the Supernus name and stock ticker, although Indivior's shareholders now own 56.5% of the new Supernus, and pre-merger Supernus shareholders own 43.5% of the new entity.

The transaction is also expected to generate $125 million in annual cost savings, giving Supernus additional financial flexibility to invest in drug development and expand its commercial operations. These anticipated savings are an important part of the merger's financial rationale, with the combined company looking to improve profitability while building on its existing product lineup.

The combined company's portfolio includes 11 approved drugs, a valuable asset for any biotech. These drugs are used in addiction treatment, psychiatry, and neurology, and five of them – Sublocade, Qelbree, Gocovri, Onapgo, and Zurzuvae – are considered growth drivers. Having this portfolio allows the company to plan for long-term expansion with a solid foundation.

Supernus also entered the merger following a strong third quarter, with revenue rising 18% year-over-year to $226.8 million. Sales from its four growth products increased 29% to $192.2 million, including $90.8 million from Qelbree and a record $42.6 million from Gocovri. These results reflect the performance of Supernus before its combination with Indivior.

Shares of the newly combined Supernus began trading under the SUPN ticker on November 3, following the completion of the merger a day earlier.

In his coverage of SUPN for Bank of America, analyst Chi Fong sees upside in the combined company's growth prospects, believing Wall Street has yet to fully appreciate its earnings potential.

"We believe the company's transition to a diversified CNS leader is underappreciated. Onapgo, Qelbree and Zurzuvae are expected to drive majority of topline growth into early 2030s, while Sublocade diversifies the business beyond those assets' later LOE risk… In our view, SUPN will have superior earnings power – which we don't think the Street fully appreciates. We expect the merger to at least double legacy Supernus' revenue and EBITDA next year. Thus, we forecast 2027 sales of ~$2.5bn and EBITDA of $1.2bn versus consensus of $1.9bn and $1.1bn. For 2028, our revenue and EBITDA estimates are 16% and 12% above consensus. FY27 guidance on SUPN's 4Q call (in February) could provide a near-term catalyst for better earnings visibility and multiple expansion," Fong opined.

Quantifying this stance, Fong rates SUPN shares as a Buy, and his $47 price target implies a ~60% upside potential on the one-year horizon. (To watch Fong's track record, click here)

The 6 recent analyst reviews here include 5 Buys and 1 Hold, supporting that Strong Buy consensus rating. The stock's $29.45 trading price and $52.60 average target price together suggest a potential upside of ~79% by the end of next year. (See SUPN stock forecast)

*Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.*

### Related Stocks

- [IAM.US](https://longbridge.com/en/quote/IAM.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BAYN.DE](https://longbridge.com/en/quote/BAYN.DE.md)
- [4502.JP](https://longbridge.com/en/quote/4502.JP.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)
- [BAC.US](https://longbridge.com/en/quote/BAC.US.md)

## Related News & Research

- [Iambic CEO Joins AI Drug Discovery Panel at Jefferies Global Healthcare Conference](https://longbridge.com/en/news/304855723.md)
- [IAM: Pipeline progress and $455M pro forma cash position support planned 2027 milestones](https://longbridge.com/en/news/305676390.md)
- [Iambic Therapeutics, Inc. GAAP EPS of -$8.52 misses by $7.75, revenue of $11.4M beats by $3.11M](https://longbridge.com/en/news/305698417.md)
- [Jim Cramer says Nvidia’s leadership shake-up won’t derail the AI trade](https://longbridge.com/en/news/305736094.md)
- [Lilly to buy Calytrix Bio for up to $1.5 billion](https://longbridge.com/en/news/305668502.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**